O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine

O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine Property

Melting point:

34-37 °C (lit.)

Boiling point:

81 °C/20 mmHg (lit.)

Density 

1.1274 (rough estimate)

refractive index 

1.4206 (estimate)

Flash point:

180 °F

storage temp. 

Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

solubility 

DMSO (Slightly), Methanol (Slightly)

pka

3.28±0.20(Predicted)

form 

Low Melting Solid

color 

White

InChI

InChI=1S/C5H11NO2/c6-8-5-3-1-2-4-7-5/h5H,1-4,6H2

InChIKey

NLXXVSKHVGDQAT-UHFFFAOYSA-N

SMILES

NOC1OCCCC1

Safety

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36

WGK Germany 

3

HS Code 

29329990

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine Chemical Properties,Usage,Production

Chemical Properties

White powder

Uses

O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine can be used to treat fibrotic and inflammatory diseases.

Uses

O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine is used as an oximation reagent in the synthesis of a marine alkaloid which shows significant inhibitory activity against mycothiol S-conjugate amidase.

General Description

O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine (OTX) is an O-substituted hydroxylamine. The coupling of OTX with alkaline gel electrophoresis has been reported to improve the process of detecting single strand breaks (SSBs) in DNA.

Synthesis

General procedure for the synthesis of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine from 3,4-dihydro-2H-pyran: N-hydroxyphthalimide (10 g, 0.061 mol) and 3,4-dihydro-2H-pyran (6.1 g, 0.073 mol) were added to a 250 mL three-necked flask, and tetrahydrofuran (100 mL) was added to dissolve. Subsequently, p-toluenesulfonic acid (1.1 g, 6.1 mmol) was added to catalyze the reaction. The reaction was carried out at room temperature for 2 hours. Upon completion of the reaction, the tetrahydrofuran was removed by distillation under reduced pressure. Water (200 mL) was added to the residue and extracted with dichloromethane (3 x 200 mL). The organic phases were combined and washed sequentially with saturated aqueous NaHCO3 solution (3 x 200 mL) and saturated aqueous NaCl solution (200 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to dryness to give a yellow-green solid (15.3 g). The resulting solid was transferred to a 1000 mL three-necked flask and ethanol (450 mL) was added and stirred to dissolve. 80% hydrazine hydrate (10.4 mL, 0.17 mol) was slowly added dropwise and the reaction was carried out for 1 hour at room temperature. The reaction solution was directly filtrated and the filtrate was evaporated to give the crude product (10.6 g). The crude product was dissolved with ethyl acetate (500 mL), mixed thoroughly and vacuum filtered to remove insoluble matter. The filtrate was washed with water (3×100 mL) and saturated NaCl aqueous solution (200 mL) sequentially, dried with anhydrous sodium sulfate and filtered, evaporated to dryness to obtain a light yellow oil. The oily material was dried under vacuum to give a yellow solid (5.39 g) with a melting point of 35-37 °C and a yield of 75.3%.

References

[1] Organic Letters, 2006, vol. 8, # 18, p. 4035 - 4038
[2] Patent: CN107400131, 2017, A. Location in patent: Paragraph 0031; 0063-0065
[3] Journal of Medicinal Chemistry, 1996, vol. 39, # 21, p. 4197 - 4210
[4] Patent: WO2012/96832, 2012, A2
[5] Chemical and Pharmaceutical Bulletin, 2014, vol. 62, # 2, p. 168 - 175